Mission Pharmacal subsidiary ProSolus Inc. said this week that it expanded its manufacturing capabilities and commercialization efforts for transdermal drug delivery technologies.
The Miami-based company, which develops and manufactures transdermal and trans-mucosal drug delivery products, installed a 2nd transdermal production facility in Boerne, Texas. The new location has a larger production line than the Miami site, according to ProSolus, and the 2 sites have a combined annual capacity of more than 100 million patches.
“For us, it’s all about the convenience and wear-ability of patches – creating more desirable, smaller sizes that stay in place while working effectively,” chief operating officer & chief scientific officer Juan Mantelle said in prepared remarks. “We are consistently searching for new and better ways to bring transdermal products to market.”
Transdermal patches deliver medication through skin and into the bloodstream. Transdermal systems tend to use lower doses of active ingredients, ProSolus said, and therefore can lessen harsh side effects more efficiently than other drug delivery techniques.
The company also launched a new commercial team, lead by Jim Self, to seek out partnerships between ProSolus and companies in the pharmaceutical industry.
“We look forward to increased partnerships with a wide array of pharmaceutical companies looking to commercialize products utilizing leading transdermal patch technology,” Self said. “Together we will be able to efficiently develop what are normally considered high-barrier-to-entry solutions and expand the overall transdermal market space, ultimately improving the care and treatment of patients.”
